600222.SS
Henan Taloph Pharmaceutical Stock Co.,Ltd [600222.SS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
600222.SS Stock Summary
Top 10 Correlated ETFs
600222.SS
Top 10 Correlated Stocks
600222.SS
In the News
600222.SS Financial details
Company Rating
Buy
Market Cap
3.17B
Income
43.56M
Revenue
2.07B
Book val./share
2.82
Cash/share
0.63
Dividend
-
Dividend %
-
Employees
2.35K
Optionable
No
Shortable
Yes
Earnings
26 Apr 2024
P/E
-95.67
Forward P/E
-
PEG
5.93
P/S
1.56
P/B
2.27
P/C
7.51
P/FCF
-40.38
Quick Ratio
0.79
Current Ratio
1.07
Debt / Equity
0.46
LT Debt / Equity
0.11
-
-
EPS (TTM)
0.08
EPS next Y
-
EPS next Q
-
EPS this Y
-159.54%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-0.63%
Revenue last 5Y
9.45%
Revenue Q/Q
38.86%
EPS Q/Q
187.21%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-28.57%
Inst Own
-
Inst Trans
-
ROA
-1%
ROE
-2%
ROC
-0.03%
Gross Margin
26%
Oper. Margin
-2%
Profit Margin
-2%
Payout
-155%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.75-8.08
52W High
-40.88%
52W Low
+57.67%
RSI
41
Rel Volume
1.26
Avg Volume
16.82M
Volume
21.23M
Perf Week
-10.42%
Perf Month
-4.64%
Perf Quarter
-17.02%
Perf Half Y
-19.69%
-
-
-
-
Beta
0.616
-
-
Volatility
0.36%, 0.22%
Prev Close
-4.83%
Price
4.73
Change
3.05%
600222.SS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.36 | 2.59 | 2.86 | 3.46 | 3.66 | |
| Net income per share | 0.08 | 0.05 | 0.01 | -0.13 | 0.08 | |
| Operating cash flow per share | 0.08 | 0.13 | 0.18 | -0.22 | 0.18 | |
| Free cash flow per share | -0.12 | 0 | 0.11 | -0.34 | 0.1 | |
| Cash per share | 1.03 | 1.27 | 1.19 | 0.68 | 0.62 | |
| Book value per share | 2.36 | 2.66 | 2.96 | 2.77 | 2.8 | |
| Tangible book value per share | 1.7 | 2.14 | 2.53 | 2.21 | 2.24 | |
| Share holders equity per share | 2.36 | 2.66 | 2.96 | 2.77 | 2.8 | |
| Interest debt per share | 2.16 | 2.5 | 2.25 | 1.27 | 1.39 | |
| Market cap | 2.54B | 2.74B | 5.03B | 3.61B | 3.47B | |
| Enterprise value | 3.28B | 3.54B | 5.83B | 3.96B | 4.09B | |
| P/E ratio | 55.57 | 93.64 | 839.25 | -47.68 | 79.72 | |
| Price to sales ratio | 1.94 | 1.93 | 3.14 | 1.84 | 1.69 | |
| POCF ratio | 58.13 | 37.29 | 50.49 | -29.02 | 35.13 | |
| PFCF ratio | -39.71 | 3.53K | 83.06 | -18.9 | 62.33 | |
| P/B Ratio | 1.94 | 1.88 | 3.03 | 2.3 | 2.2 | |
| PTB ratio | 1.94 | 1.88 | 3.03 | 2.3 | 2.2 | |
| EV to sales | 2.5 | 2.5 | 3.63 | 2.02 | 1.99 | |
| Enterprise value over EBITDA | 18.32 | 21.96 | 31 | 43.74 | 25.53 | |
| EV to operating cash flow | 75.02 | 48.26 | 58.47 | -31.8 | 41.43 | |
| EV to free cash flow | -51.24 | 4.57K | 96.19 | -20.71 | 73.51 | |
| Earnings yield | 0.02 | 0.01 | 0 | -0.02 | 0.01 | |
| Free cash flow yield | -0.03 | 0 | 0.01 | -0.05 | 0.02 | |
| Debt to equity | 0.87 | 0.89 | 0.71 | 0.42 | 0.46 | |
| Debt to assets | 0.41 | 0.38 | 0.31 | 0.18 | 0.2 | |
| Net debt to EBITDA | 4.12 | 4.99 | 4.23 | 3.83 | 3.88 | |
| Current ratio | 1.93 | 1.25 | 1.18 | 1.18 | 1.21 | |
| Interest coverage | 2.18 | 1.61 | 1.59 | 0.44 | 1.63 | |
| Income quality | 0.97 | 2.66 | 14.7 | 1.64 | 2.27 | |
| Dividend Yield | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | |
| Payout ratio | 1.31 | 2.24 | 14.1 | -0.84 | 1.15 | |
| Sales general and administrative to revenue | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | |
| Research and developement to revenue | 0.05 | 0.04 | 0.04 | 0.06 | 0.06 | |
| Intangibles to total assets | 0.13 | 0.11 | 0.09 | 0.1 | 0.1 | |
| Capex to operating cash flow | -2.46 | -0.99 | -0.39 | 0.54 | -0.44 | |
| Capex to revenue | -0.08 | -0.05 | -0.02 | -0.03 | -0.02 | |
| Capex to depreciation | -2.73 | -1.75 | -0.68 | -1.06 | -0.57 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0.01 | -0.14 | |
| Graham number | 2.09 | 1.79 | 0.84 | 2.89 | 2.21 | |
| ROIC | 0.05 | 0.04 | 0.04 | 0.01 | 0.04 | |
| Return on tangible assets | 0.02 | 0.01 | 0 | -0.02 | 0.01 | |
| Graham Net | -0.12 | -0.67 | -0.86 | -0.86 | -0.96 | |
| Working capital | 834.36M | 378.49M | 294.03M | 305.21M | 342.93M | |
| Tangible asset value | 943.87M | 1.17B | 1.42B | 1.25B | 1.26B | |
| Net current asset value | 299.21M | 23.55M | -62.43M | 45.14M | 42.87M | |
| Invested capital | 0.87 | 0.89 | 0.71 | 0.42 | 0.46 | |
| Average receivables | 733.33M | 839.97M | 860.96M | 1.04B | 1.15B | |
| Average payables | 151.07M | 177.25M | 283.68M | 452.27M | 489.59M | |
| Average inventory | 297.86M | 324.05M | 365M | 416.17M | 452.99M | |
| Days sales outstanding | 235.49 | 214.7 | 202.08 | 220.83 | 197.07 | |
| Days payables outstanding | 62.98 | 74.14 | 113.72 | 134.59 | 102.56 | |
| Days of inventory on hand | 132.31 | 121.92 | 122.1 | 110.46 | 108.57 | |
| Receivables turnover | 1.55 | 1.7 | 1.81 | 1.65 | 1.85 | |
| Payables turnover | 5.8 | 4.92 | 3.21 | 2.71 | 3.56 | |
| Inventory turnover | 2.76 | 2.99 | 2.99 | 3.3 | 3.36 | |
| ROE | 0.03 | 0.02 | 0 | -0.05 | 0.03 | |
| Capex per share | -0.19 | -0.13 | -0.07 | -0.12 | -0.08 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.17 | 0.99 | 0.78 | 0.8 | 1.11 | |
| Net income per share | -0.03 | 0.01 | -0.08 | 0.04 | 0.11 | |
| Operating cash flow per share | -0.03 | 0.01 | 0.03 | 0.12 | 0.17 | |
| Free cash flow per share | -0.1 | -0.01 | 0.02 | 0.1 | 0.15 | |
| Cash per share | 0.68 | 0.49 | 0.47 | 0.44 | 0.63 | |
| Book value per share | 2.77 | 2.74 | 2.54 | 2.59 | 2.82 | |
| Tangible book value per share | 2.21 | 2.18 | 1.96 | 2.01 | 2.26 | |
| Share holders equity per share | 2.77 | 2.74 | 2.54 | 2.59 | 2.82 | |
| Interest debt per share | 1.19 | 1.23 | 1.31 | 1.2 | 1.33 | |
| Market cap | 3.61B | 3.33B | 3.29B | 3.13B | 3.45B | |
| Enterprise value | 3.96B | 3.76B | 3.81B | 3.6B | 4.07B | |
| P/E ratio | -51.72 | 225.82 | -19.57 | 36.52 | 14.27 | |
| Price to sales ratio | 5.44 | 5.94 | 7.59 | 6.96 | 5.54 | |
| POCF ratio | -206.89 | 903.3 | 188.37 | 47.84 | 35.67 | |
| PFCF ratio | -65.14 | -535.39 | 351.35 | 58.14 | 41.48 | |
| P/B Ratio | 2.3 | 2.14 | 2.32 | 2.16 | 2.19 | |
| PTB ratio | 2.3 | 2.14 | 2.32 | 2.16 | 2.19 | |
| EV to sales | 5.96 | 6.72 | 8.79 | 8.03 | 6.53 | |
| Enterprise value over EBITDA | 273.63 | 269.74 | -126.82 | 134.57 | 45.65 | |
| EV to operating cash flow | -226.73 | 1.02K | 218.23 | 55.14 | 42.1 | |
| EV to free cash flow | -71.39 | -605.87 | 407.04 | 67.02 | 48.96 | |
| Earnings yield | 0 | 0 | -0.01 | 0.01 | 0.02 | |
| Free cash flow yield | -0.02 | 0 | 0 | 0.02 | 0.02 | |
| Debt to equity | 0.42 | 0.44 | 0.51 | 0.45 | 0.46 | |
| Debt to assets | 0.18 | 0.19 | 0.21 | 0.2 | 0.2 | |
| Net debt to EBITDA | 23.95 | 31.38 | -17.35 | 17.83 | 6.98 | |
| Current ratio | 1.18 | 1.04 | 1.04 | 1.07 | 1.21 | |
| Interest coverage | -1.36 | 0.23 | -3.85 | 2.13 | 5.25 | |
| Income quality | 1 | 1 | -0.42 | 3.05 | 1.6 | |
| Dividend Yield | 0.01 | 0.01 | 0 | 0 | 0.01 | |
| Payout ratio | -1.18 | 5.77 | 0 | 0.53 | 0.29 | |
| Sales general and administrative to revenue | -0.07 | 0.06 | -0.01 | 0.17 | -0.09 | |
| Research and developement to revenue | 0.07 | 0.04 | 0.13 | 0.05 | 0.04 | |
| Intangibles to total assets | 0.1 | 0.1 | 0.11 | 0.11 | 0.1 | |
| Capex to operating cash flow | 2.18 | -2.69 | -0.46 | -0.18 | -0.14 | |
| Capex to revenue | -0.06 | -0.02 | -0.02 | -0.03 | -0.02 | |
| Capex to depreciation | -2.15 | -0.51 | -0.42 | 0.33 | -0.73 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.39 | 0.63 | 2.07 | 1.49 | 2.62 | |
| ROIC | -0.01 | 0 | -0.02 | 0.01 | 0.03 | |
| Return on tangible assets | -0.01 | 0 | -0.01 | 0.01 | 0.02 | |
| Graham Net | -0.86 | -0.95 | -1.07 | -0.96 | -0.96 | |
| Working capital | 305.21M | 75.73M | 64.52M | 115.38M | 342.93M | |
| Tangible asset value | 1.25B | 1.23B | 1.09B | 1.12B | 1.26B | |
| Net current asset value | 45.14M | 6.98M | -74.21M | -10.62M | 42.87M | |
| Invested capital | 0.42 | 0.44 | 0.51 | 0.45 | 0.46 | |
| Average receivables | 1.15B | 1.22B | 1.2B | 1.13B | 1.12B | |
| Average payables | 520.59M | 557.05M | 549.9M | 495.49M | 443.34M | |
| Average inventory | 410.68M | 441.86M | 444.35M | 453.82M | 453.83M | |
| Days sales outstanding | 160.92 | 201.53 | 236 | 225.16 | 160.57 | |
| Days payables outstanding | 100.58 | 125.03 | 140.11 | 125.35 | 89.09 | |
| Days of inventory on hand | 82.54 | 95.84 | 119.37 | 124.19 | 94.31 | |
| Receivables turnover | 0.56 | 0.45 | 0.38 | 0.4 | 0.56 | |
| Payables turnover | 0.89 | 0.72 | 0.64 | 0.72 | 1.01 | |
| Inventory turnover | 1.09 | 0.94 | 0.75 | 0.72 | 0.95 | |
| ROE | -0.01 | 0 | -0.03 | 0.01 | 0.04 | |
| Capex per share | -0.07 | -0.02 | -0.01 | -0.02 | -0.02 |
600222.SS Frequently Asked Questions
What is Henan Taloph Pharmaceutical Stock Co.,Ltd stock symbol ?
Henan Taloph Pharmaceutical Stock Co.,Ltd is a CN stock and trading under the symbol 600222.SS
What is Henan Taloph Pharmaceutical Stock Co.,Ltd stock quote today ?
Henan Taloph Pharmaceutical Stock Co.,Ltd stock price is $4.73 today.
Is Henan Taloph Pharmaceutical Stock Co.,Ltd stock public?
Yes, Henan Taloph Pharmaceutical Stock Co.,Ltd is a publicly traded company.
Company Profile
- Volume Average 16.82M
- Market Capitalization 3.17B
- Employee 2.35K
- CEO Mr. Jianchao Luo
- Headquarters Zhengzhou,CN
- IPO Date 1999-11-05
-
Website
https://www.taloph.com 
Henan Taloph Pharmaceutical Stock Co., Ltd. researches, produces, and sells Chinese and western medicines in China. It primarily offers its products in the forms of oral liquids, tablets, capsules, fluids, and other forms. The company's principal products include Huperzine A tablets, phenoxybenzamine hydrochloride tablets, pazufloxacin mesylate sodium chloride injections, and various infusion products. It serves hospitals, pharmacies, and patients. The company was formerly known as Henan Joyline & Joysun Pharmaceutical Stock Co., Ltd. Henan Taloph Pharmaceutical Stock Co., Ltd. is based in Zhengzhou, China.
